NEW YORK, June 4-ActivX Biosciences has inked a deal with Tokyo's Kyorin Pharmaceutical company to identify and optimize new drugs for type II diabetes, the company said today.
ActivX, which studies protein activity in disease, will develop assays, screen and profile hit and lead compounds. Kyorin will provide the company with research support, milestone payments, and royalties on any commercialized products. ActivX also retains rights for some compounds that may be active in other diseases.
Kyorin will conduct medicinal chemistry, animal pharmacology and clinical development on lead compounds. The company has worldwide manufacturing and marketing rights to any drugs developed in the collaboration.
ActivX is the Japanese pharmaceutical company's first U.S. biotechnology partner.
Based in La Jolla, ActivX studies disease mechanisms by analyzing protein activity.
For further details, read the press release.